Liquidia Corp (LQDA)
10.46
-0.52
(-4.74%)
USD |
NASDAQ |
Nov 04, 16:00
10.50
+0.04
(+0.38%)
After-Hours: 20:00
Liquidia Revenue (Quarterly): 3.659M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 3.659M |
March 31, 2024 | 2.972M |
December 31, 2023 | 4.531M |
September 30, 2023 | 3.678M |
June 30, 2023 | 4.786M |
March 31, 2023 | 4.493M |
December 31, 2022 | 5.36M |
September 30, 2022 | 3.165M |
June 30, 2022 | 3.918M |
March 31, 2022 | 3.492M |
December 31, 2021 | 3.215M |
September 30, 2021 | 3.179M |
June 30, 2021 | 3.376M |
March 31, 2021 | 3.084M |
December 31, 2020 | 0.7396M |
Date | Value |
---|---|
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | 8.072M |
March 31, 2019 | |
December 31, 2018 | 0.5684M |
September 30, 2018 | 0.1697M |
June 30, 2018 | 1.043M |
March 31, 2018 | 0.926M |
December 31, 2017 | 1.816M |
September 30, 2017 | 1.821M |
June 30, 2017 | 1.982M |
March 31, 2017 | 1.639M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.7396M
Minimum
Dec 2020
5.36M
Maximum
Dec 2022
3.576M
Average
3.492M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
United Therapeutics Corp | 748.90M |
Arcturus Therapeutics Holdings Inc | 45.98M |
Paragon 28 Inc | 61.02M |
Tonix Pharmaceuticals Holding Corp | 2.208M |
AIM ImmunoTech Inc | 0.05M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -27.94M |
Total Expenses (Quarterly) | 30.86M |
EPS Diluted (Quarterly) | -0.37 |
Enterprise Value | 749.50M |
Gross Profit Margin (Quarterly) | 59.20% |
Profit Margin (Quarterly) | -763.7% |
Earnings Yield | -15.01% |
Normalized Earnings Yield | -13.55 |